Target type: biologicalprocess
The attachment of one cell to another cell via an integrin, a heterodimeric adhesion receptor formed by the non-covalent association of particular alpha and beta subunits. [GOC:add, PMID:12213832, PMID:14754902]
Cell-cell adhesion mediated by integrins is a fundamental process in multicellular organisms, enabling cells to interact and form tissues and organs. Integrins, transmembrane receptors, play a crucial role in this process by acting as bridges between the extracellular matrix (ECM) and the intracellular cytoskeleton.
**1. Ligand Binding:**
* Integrins bind to specific ligands on the surface of other cells or the ECM. These ligands can include proteins like cadherins, immunoglobulin superfamily members, and ECM components like fibronectin, collagen, and laminin.
**2. Conformational Changes:**
* Upon ligand binding, integrins undergo conformational changes, transitioning from a low-affinity state to a high-affinity state. This change involves a shift in the extracellular domain, exposing the binding site for intracellular signaling molecules.
**3. Clustering and Adhesion:**
* Multiple integrin molecules can cluster together at sites of cell-cell adhesion. This clustering is facilitated by interactions with other cell adhesion molecules, such as cadherins.
* The clustering of integrins strengthens the adhesive bond between cells, leading to stable cell-cell contact.
**4. Intracellular Signaling:**
* Integrin activation triggers intracellular signaling pathways. The cytoplasmic tails of integrins interact with various adaptor proteins and signaling molecules, including focal adhesion kinase (FAK) and the Src family kinases.
* These signaling pathways regulate cellular processes such as cytoskeletal reorganization, cell migration, proliferation, and differentiation.
**5. Force Transmission:**
* Integrins are involved in force transmission between the ECM and the cell. This force can be generated by cellular contractile machinery, such as actin filaments, and is essential for cell migration, tissue morphogenesis, and wound healing.
**6. Cell-Cell Communication:**
* Integrin-mediated cell-cell adhesion also facilitates cell-cell communication. The clustering of integrins and associated signaling molecules can create signaling complexes that regulate gene expression and other cellular functions.
In summary, integrin-mediated cell-cell adhesion is a complex and dynamic process involving ligand binding, conformational changes, clustering, intracellular signaling, force transmission, and cell-cell communication. This process is essential for the formation, organization, and function of tissues and organs in multicellular organisms.'
"
Protein | Definition | Taxonomy |
---|---|---|
Disintegrin and metalloproteinase domain-containing protein 9 | A disintegrin and metalloproteinase domain-containing protein 9 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q13443] | Homo sapiens (human) |
Vascular cell adhesion protein 1 | A vascular cell adhesion protein 1 that is encoded in the genome of human. [PRO:WCB, UniProtKB:P19320] | Homo sapiens (human) |
Integrin alpha-4 | An integrin alpha-4 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P13612] | Homo sapiens (human) |
Integrin alpha-5 | An integrin alpha-5 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P08648] | Homo sapiens (human) |
Integrin beta-1 | An integrin beta-1 that is encoded in the genome of human. [PRO:WCB, UniProtKB:P05556] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
bupropion | bupropion : An aromatic ketone that is propiophenone carrying a tert-butylamino group at position 2 and a chloro substituent at position 3 on the phenyl ring. Bupropion: A propiophenone-derived antidepressant and antismoking agent that inhibits the uptake of DOPAMINE. | aromatic ketone; monochlorobenzenes; secondary amino compound | antidepressant; environmental contaminant; xenobiotic |
haloperidol | haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety. Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279) | aromatic ketone; hydroxypiperidine; monochlorobenzenes; organofluorine compound; tertiary alcohol | antidyskinesia agent; antiemetic; dopaminergic antagonist; first generation antipsychotic; serotonergic antagonist |
probucol | probucol : A dithioketal that is propane-2,2-dithiol in which the hydrogens attached to both sulfur atoms are replaced by 3,5-di-tert-butyl-4-hydroxyphenyl groups. An anticholesteremic drug with antioxidant and anti-inflammatory properties, it is used to treat high levels of cholesterol in blood. Probucol: A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993). | dithioketal; polyphenol | anti-inflammatory drug; anticholesteremic drug; antilipemic drug; antioxidant; cardiovascular drug |
1,3-ditolylguanidine | 1,3-ditolylguanidine: structure given in first source; a selective ligand for the sigma binding sites in the brain | toluenes | |
difluorodinitrobenzene sulfone | |||
tirofiban | tirofiban : A member of the class of piperidines that is L-tyrosine in which a hydrogen attached to the amino group is replaced by a butylsulfonyl group and in which the hydrogen attached to the phenolic hydroxy group is replaced by a 4-(piperidin-4-yl)butyl group. Tirofiban: Tyrosine analog and PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX antagonist that inhibits PLATELET AGGREGATION and is used in the treatment of ACUTE CORONARY SYNDROME. | L-tyrosine derivative; piperidines; sulfonamide | anticoagulant; fibrin modulating drug; platelet glycoprotein-IIb/IIIa receptor antagonist |
arginyl-glycyl-aspartic acid | arginyl-glycyl-aspartic acid: amino acid sequence of basic unit of widespread cellular recognition system | oligopeptide | |
arginyl-glycyl-aspartyl-serine | arginyl-glycyl-aspartyl-serine: corresponds to cell attachment site of fibronectin; located near carboxyl-terminal region of alpha-chain of fibrinogen; inhibits platelet aggregation & fibrinogen binding to activated platelets | ||
glycyl-arginyl-glycyl-aspartyl-serine | glycyl-arginyl-glycyl-aspartyl-serine: synthetic peptide from fibronectins; inhibits experimental metastasis of murine melanoma cells | ||
ilomastat | CS 610: matrix metalloproteinase inhibitor; structure in first source ilomastat : An N-acyl-amino acid obtained by formal condensation of the carboxy group of (2R)-2-[2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoic acid with the amino group of N-methyl-L-tryptophanamide. A cell permeable broad-spectrum matrix metalloproteinase (MMP) inhibitor | hydroxamic acid; L-tryptophan derivative; N-acyl-amino acid | anti-inflammatory agent; antibacterial agent; antineoplastic agent; EC 3.4.24.24 (gelatinase A) inhibitor; neuroprotective agent |
d-arg-gly-asp-trp | arginyl-glycyl-aspartyl-tryptophan: a synthetic RGD-containing peptide | ||
l 738167 | L 738167: structure in first source | ||
cilengitide | Cilengitide: an alphaVbeta3 integrin antagonist that paralyzes cancer cells | oligopeptide | |
l 734217 | L 734217: fibrinogen receptor antagonist; structure given in first source | ||
succinobucol | succinobucol: monosuccinic acid ester of probucol; a metabolically stable modification of probucol, an equipotent antioxidant to probucol but is pharmacologically distinct | benzoate ester; phenols | |
cyclopamine | piperidines | glioma-associated oncogene inhibitor | |
arginyl-glycyl-aspartyl-phenylalanine | |||
pepstatin | pepstatin: inhibits the aspartic protease endothiapepsin | pentapeptide; secondary carboxamide | bacterial metabolite; EC 3.4.23.* (aspartic endopeptidase) inhibitor |
4-[(4-methylphenyl)thio]-2-thieno[2,3-c]pyridinecarboxamide | aryl sulfide | ||
cyclic(arg-gly-asp-d-phe-val) | |||
mk-0429 | |||
mocetinostat | mocetinostat : A benzamide obtained by formal condensation of the carboxy group of 4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}methyl)benzoic acid with one of the amino groups of benzene-1,2-diamine. It is an orally active and isotype-selective HDAC inhibitor which exhibits antitumour activity (IC50 = 0.15, 0.29, 1.66 and 0.59 muM for HDAC1, HDAC2, HDAC3 and HDAC11). mocetinostat: undergoing phase II clinical trials for treatment of cancer | aminopyrimidine; benzamides; pyridines; secondary amino compound; secondary carboxamide; substituted aniline | antineoplastic agent; apoptosis inducer; autophagy inducer; cardioprotective agent; EC 3.5.1.98 (histone deacetylase) inhibitor; hepatotoxic agent |
tr 14035 | N-(2,6-dichlorobenzoyl)-4-(2',6'-bismethoxyphenyl)phenylalanine: TR-14035 is the (L)-isomer; an antagonist of both alpha4beta1 and beta7 integrins; structure in first source | ||
bio 1211 | BIO 1211: integrin alpha4beta1 inhibitor; structure in first source | ||
incb3619 | INCB3619: ADAM inhibitor; structure in first source | ||
grassystatin a | grassystatin A: isolated from a cyanobacterium, identified as Lyngbya cf.; structure in first source |